Home  |  Contact

Cellosaurus Hep 3B2.1-7 (CVCL_0326)

[Text version]

Cell line name Hep 3B2.1-7
Synonyms Hep 3B2_1-7; HEP3B217; Hep 3B2; HEP-3B2; HEP3B2; Hep-3B; HEP-3B; Hep 3B; Hep3B; HEP3B
Accession CVCL_0326
Resource Identification Initiative To cite this cell line use: Hep 3B2.1-7 (RRID:CVCL_0326)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: JFCR45 cancer cell line panel.
Part of: Liver Cancer Model Repository (LIMORE).
Part of: MD Anderson Cell Lines Project.
Part of: TCGA-110-CL cell line panel.
Doubling time: 28.05 hours (PubMed=31378681); ~40-50 hours (DSMZ).
Karyotypic information: Has lost chromosome Y.
Microsatellite instability: Stable (MSS) (Sanger).
Transformant: NCBI_TaxID; 10407; Hepatitis B virus (HBV).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Genome sequenced.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Homozygous for AXIN1 p.Arg146Ter (c.436C>T) (PubMed=31395879; CCLE; Cosmic-CLP).
Homozygous for RB1 p.Ser576Ter (c.1727C>G) (PubMed=31395879; CCLE; Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African2.83
Native American20.88
East Asian, North4.48
East Asian, South0
South Asian0
European, North22.82
European, South48.99
Disease Childhood hepatocellular carcinoma (NCIt: C7955)
Pediatric hepatocellular carcinoma (ORDO: Orphanet_33402)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_XE51 (Hep3b-Cas9-741)CVCL_XE52 (Hep3b-Cas9-742)CVCL_XE53 (Hep3b-Cas9-743)
CVCL_XE54 (Hep3b-Cas9-744)CVCL_XE55 (Hep3b-Cas9-745)CVCL_DI39 (Hep3BLAP-I)
CVCL_DI40 (Hep3BLAP-II)CVCL_DI41 (Hep3BLIP-I)CVCL_DI42 (Hep3BLIP-II)
CVCL_W815 (REPC)
Sex of cell Male
Age at sampling 8Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CCRID; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=24116068; PubMed=25877200; PubMed=31378681

Markers:
AmelogeninX
CSF1PO8
D2S133821,25
D3S135815
D5S81813
D7S8208,10
D8S117912
D13S31712,14
D16S53910
D18S5120
D19S43312.2,14
D21S1130,31
FGA18
Penta D12,14
Penta E5,16
TH016,7
TPOX9
vWA17

Run an STR similarity search on this cell line
Web pages http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/h/cell-lines-detail-106.html
https://www.quora.com/What-is-a-Hep-3B-cell-line
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=431
http://www.cellresource.cn/fdetail.aspx?id=674
http://www.cellresource.cn/fdetail.aspx?id=837
http://www.cellresource.cn/fdetail.aspx?id=1565
http://www.cellresource.cn/fdetail.aspx?id=2147
http://www.brics.ac.cn/article-template.html?articleId=411&columnId=18
Publications

PubMed=233137; DOI=10.1038/282615a0
Aden D.P., Fogel A., Plotkin S.A., Damjanov I., Knowles B.B.
Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line.
Nature 282:615-616(1979)

PubMed=6248960; DOI=10.1126/science.6248960
Knowles B.B., Howe C.C., Aden D.P.
Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen.
Science 209:497-499(1980)

PubMed=6275024; DOI=10.1099/0022-1317-57-1-95
Koshy R., Maupas P., Muller R., Hofschneider P.H.
Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcinoma and liver cirrhosis tissues.
J. Gen. Virol. 57:95-102(1981)

Patent=US4393133
Knowles B.B., Aden D.P.
Human hepatoma derived cell line, process for preparation thereof, and uses therefor.
Patent number US4393133, 12-Jul-1983

PubMed=3023526; DOI=10.1099/0022-1317-67-11-2315
Aspinall S., Alexander J., Bos P.
Comparative expression of hepatitis B virus antigens in several cell model systems.
J. Gen. Virol. 67:2315-2323(1986)

DOI=10.1007/978-4-431-68349-0_4
Alexander J.J.
Human hepatoma cell lines.
(In) Neoplasms of the liver; Okuda K., Ishak K.G. (eds.); pp.47-56; Springer; Tokyo (1987)

PubMed=2439335; DOI=10.1111/j.1432-1033.1987.tb11497.x
Vincent C., Marceau M., Blangarin P., Bouic P., Madjar J.J., Revillard J.-P.
Purification of alpha 1-microglobulin produced by human hepatoma cell lines. Biochemical characterization and comparison with alpha 1-microglobulin synthesized by human hepatocytes.
Eur. J. Biochem. 165:699-704(1987)

PubMed=8389256; DOI=10.1093/carcin/14.5.987
Hsu I.C., Tokiwa T., Bennett W., Metcalf R.A., Welsh J.A., Sun T., Harris C.C.
p53 gene mutation and integrated hepatitis B viral DNA sequences in human liver cancer cell lines.
Carcinogenesis 14:987-992(1993)

PubMed=8050184; DOI=10.1111/j.1365-2249.1994.tb06089.x
Wadee A.A., Paterson A., Coplan K.A., Reddy S.G.
HLA expression in hepatocellular carcinoma cell lines.
Clin. Exp. Immunol. 97:328-333(1994)

PubMed=8835345; DOI=10.1002/(SICI)1096-9071(199602)48:2<133::AID-JMV3>3.0.CO;2-A
Tsuboi S., Nagamori S., Miyazaki M., Mihara K., Fukaya K., Teruya K., Kosaka T., Tsuji T., Namba M.
Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines.
J. Med. Virol. 48:133-140(1996)

DOI=10.11418/jtca1981.16.3_173
Mihara K., Miyazaki M., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ohashi R., Namba M.
The p53 gene status and other cellular characteristics of human cell lines maintained in our laboratory.
Tissue Cult. Res. Commun. 16:173-178(1997)

PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)

PubMed=9359923; DOI=10.18926/AMO/30789
Mihara K., Miyazaki M., Kondo T., Fushimi K., Tsuji T., Inoue Y., Fukaya K.-I., Ishioka C., Namba M.
Yeast functional assay of the p53 gene status in human cell lines maintained in our laboratory.
Acta Med. Okayama 51:261-265(1997)

PubMed=10523694; DOI=10.3892/or.6.6.1267
Gao C., Ohashi R., Pu H., Inoue Y., Tsuji T., Miyazaki M., Namba M.
Yeast functional assay of the p53 gene status in 11 cell lines and 26 surgical specimens of human hepatocellular carcinoma.
Oncol. Rep. 6:1267-1271(1999)

PubMed=11050057; DOI=10.1053/jhep.2000.19349
Wong N., Lai P., Pang E., Leung T.W.-T., Lau J.W.-L., Johnson P.J.
A comprehensive karyotypic study on human hepatocellular carcinoma by spectral karyotyping.
Hepatology 32:1060-1068(2000)

PubMed=12029633; DOI=10.1053/jhep.2002.33683
Yasui K., Arii S., Zhao C., Imoto I., Ueda M., Nagai H., Emi M., Inazawa J.
TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas.
Hepatology 35:1476-1484(2002)

PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234
Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T.
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.
Mol. Cancer Ther. 4:399-412(2005)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=20454443; DOI=10.1155/2010/904767
Uphoff C.C., Denkmann S.A., Steube K.G., Drexler H.G.
Detection of EBV, HBV, HCV, HIV-1, HTLV-I and -II, and SMRV in human and other primate cell lines.
J. Biomed. Biotechnol. 2010:904767-904767(2010)

PubMed=20937217; DOI=10.1170/149
Di Masi A., Viganotti M., Antoccia A., Magrelli A., Salvatore M., Azzalin G., Tosto F., Lorenzetti S., Maranghi F., Mantovani A., Macino G., Tanzarella C., Taruscio D.
Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/beta - catenin pathway, microRNA expression and protein expression profile.
Cell. Mol. Biol. 56:OL1299-OL1317(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23505090; DOI=10.1002/hep.26402
Wang K., Lim H.Y., Shi S., Lee J., Deng S., Xie T., Zhu Z., Wang Y., Pocalyko D., Yang W.J., Rejto P.A., Mao M., Park C.-K., Xu J.
Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma.
Hepatology 58:706-717(2013)

PubMed=23887712; DOI=10.1038/ncomms3218
Nault J.-C., Mallet M., Pilati C., Calderaro J., Bioulac-Sage P., Laurent C., Laurent A., Cherqui D., Balabaud C., Zucman-Rossi J.
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions.
Nat. Commun. 4:2218-2218(2013)

PubMed=24116068; DOI=10.1371/journal.pone.0075692
Weiskirchen R., Weimer J., Meurer S.K., Kron A., Seipel B., Vater I., Arnold N., Siebert R., Xu L.-M., Friedman S.L., Bergmann C.
Genetic characteristics of the human hepatic stellate cell line LX-2.
PLoS ONE 8:E75692-E75692(2013)

PubMed=25574106; DOI=10.3748/wjg.v21.i1.311
Cevik D., Yildiz G., Ozturk M.
Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
World J. Gastroenterol. 21:311-317(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=29610054; DOI=10.1016/j.dmpk.2018.03.003
Shi J., Wang X., Lyu L., Jiang H., Zhu H.-J.
Comparison of protein expression between human livers and the hepatic cell lines HepG2, Hep3B, and Huh7 using SWATH and MRM-HR proteomics: Focusing on drug-metabolizing enzymes.
Drug Metab. Pharmacokinet. 33:133-140(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31378681; DOI=10.1016/j.ccell.2019.07.001
Qiu Z.-X., Li H., Zhang Z.-T., Zhu Z.-F., He S., Wang X.-J., Wang P.-C., Qin J.-J., Zhuang L.-P., Wang W., Xie F.-B., Gu Y., Zou K.-K., Li C., Li C., Wang C.-H., Cen J., Chen X.-T., Shu Y.-J., Zhang Z., Sun L.-L., Min L.-H., Fu Y., Huang X.-W., Lv H., Zhou H., Ji Y., Zhang Z.-G., Meng Z.-Q., Shi X.-L., Zhang H.-B., Li Y.-X., Hui L.-J.
A pharmacogenomic landscape in human liver cancers.
Cancer Cell 36:179-193.e11(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574-3574(2019)

PubMed=31978347; DOI=10.1016/j.cell.2019.12.023
Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III, Kalocsay M., Jane-Valbuena J., Gelfand E., Schweppe D.K., Jedrychowski M., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P.
Quantitative proteomics of the Cancer Cell Line Encyclopedia.
Cell 180:387-402.e16(2020)

Cross-references
Cell line collections AddexBio; C0015001/45
ATCC; HB-8064
BCRC; 60434
BCRJ; 0357
CCTCC; GDC0070
DSMZ; ACC-93
ECACC; 86062703
IZSLER; BS TCL 78
KCB; KCB 200771YJ
KCB; KCB 200942YJ
KCLB; 88064
RCB; RCB2090 - Discontinued
TKG; TKG 0291
Cell line databases/resources CLDB; cl1627
CLDB; cl1628
CLDB; cl1629
CLDB; cl1630
CCLE; HEP3B217_LIVER
CCRID; 3111C0001CCC000376
CCRID; 3111C0001CCC000474
CCRID; 3111C0002000000059
CCRID; 3131C0001000700106
CCRID; 3142C0001000000069
Cell_Model_Passport; SIDM00672
CGH-DB; 454-3
CGH-DB; 9069-4
Cosmic-CLP; 1240147
DepMap; ACH-000625
IGRhCellID; Hep3B
LIMORE; Hep3B
LINCS_LDP; LCL-1924
Lonza; 473
TOKU-E; 1439
TOKU-E; 3574
Ontologies BTO; BTO:0000972
CLO; CLO_0003702
CLO; CLO_0003703
CLO; CLO_0003710
EFO; EFO_0002205
MCCL; MCC:0000221
Biological sample resources BioSample; SAMN03473193
BioSample; SAMN10988098
Chemistry resources GDSC; 1240147
PharmacoDB; Hep3B2_17_538_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM207050
GEO; GSM501778
GEO; GSM565879
GEO; GSM887078
GEO; GSM888148
GEO; GSM936759
GEO; GSM1374531
GEO; GSM1669879
GEO; GSM2551564
Other Wikidata; Q54882746
Polymorphism and mutation databases Cosmic; 873401
Cosmic; 928140
Cosmic; 934549
Cosmic; 948066
Cosmic; 979729
Cosmic; 999851
Cosmic; 1019316
Cosmic; 1177682
Cosmic; 1351510
Cosmic; 1518225
Cosmic; 1628385
Cosmic; 2023864
Cosmic; 2162536
Cosmic; 2301557
Cosmic; 2321030
Cosmic; 2668282
IARC_TP53; 30036
LiGeA; CCLE_655
Proteomic databases PRIDE; PXD000533
PRIDE; PXD000535
PRIDE; PXD008190
Entry history
Entry creation04-Apr-2012
Last entry updated02-Jul-2020
Version number34